Common name
N-cyclohexylformamide
IUPAC name
N-cyclohexylformamide
SMILES
C1(CCCCC1)NC=O
Common name
N-cyclohexylformamide
IUPAC name
N-cyclohexylformamide
SMILES
C1(CCCCC1)NC=O
INCHI
InChI=1S/C7H13NO/c9-6-8-7-4-2-1-3-5-7/h6-7H,1-5H2,(H,8,9)
FORMULA
C7H13NO
Common name
N-cyclohexylformamide
IUPAC name
N-cyclohexylformamide
Molecular weight
127.184
clogP
1.321
clogS
-1.276
Frequency
0.0007
HBond Acceptor
1
HBond Donor
1
Total PolarSurface Area
29.1
Number of Rings
1
Rotatable Bond
1
| Drug ID | Common name | Structure CAS | Compound class | Therapeutic area |
|---|---|---|---|---|
| FDBD01659 | Edoxaban |
|
Factor Xa Inhibitors; | Edoxaban is indicated to reduce the risk of stroke and systemic embolism (SE) in patients with nonvalvular atrial fibrillation (NVAF). However, it should not be used in patients with creatinine clearance (CrCL) > 95 mL/min because of increased risk of ischemic stroke compared to warfarin at the highest dose studied (60 mg). It is also indicated for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) following 5-10 days of initial therapy with a parenteral anticoagulant. |
| FDBD02960 | furmecyclox |
|
Fungicide | Fungicide |
2 ,
1
| FRAGNAME | PDBID | SIMILIRITY | XSCORE | SMILE | HAC |
|---|---|---|---|---|---|
| 4k4e_ligand_1_4.mol2 | 4k4e | 1 | -6.82 | C(=O)NC1CCCCC1 | 9 |
| 4msg_ligand_1_4.mol2 | 4msg | 1 | -6.81 | C(=O)NC1CCCCC1 | 9 |
| 4mt9_ligand_1_0.mol2 | 4mt9 | 1 | -6.77 | C1CC(CCC1)NC=O | 9 |
| 2xfk_ligand_1_11.mol2 | 2xfk | 1 | -6.58 | C1(CCCCC1)NC=O | 9 |
| 2xfi_ligand_1_10.mol2 | 2xfi | 1 | -6.57 | C1(CCCCC1)NC=O | 9 |
| 2viy_ligand_1_10.mol2 | 2viy | 1 | -6.54 | C1(CCCCC1)NC=O | 9 |
| 4x6h_ligand_1_0.mol2 | 4x6h | 1 | -6.53 | C1(CCCCC1)NC=O | 9 |
| 2vj6_ligand_1_10.mol2 | 2vj6 | 1 | -6.52 | C(=O)NC1CCCCC1 | 9 |
107 ,
11
